Getting Your Molecule Thru the Clinic in these Challenging Times – a View from your CDMO Partners
Sponsored by Expert Insights and Orientation Marketing, a panel of senior executives from the development and manufacturing partners charged with scaling and supplying medicines to patients were optimistic about 2024, but reflected on some of the challenges the industry will face too.
Themes of innovation, time, regulation and cooperation ran through many of the topics discussed, especially with an eye toward the novel modalities and diversity of molecules in the pipeline, the panel discussed strategies to best help its partners overcome increasingly technical challenges in areas such as CMC, and drug delivery, and whether AI will be an asset or a distraction.
Supply of money and materials remained concerns and panellists hoped that funding would continue so that innovators, and especially smaller companies, could maintain the momentum necessary to develop important programmes. Would the industry’s focus toward safer programmes in Phase 2 and beyond create an innovation deficit in the future?
Time is critical, but panellists discussed how the value of time changes through a development programme and reflecting on the rate of innovation, there was discussion of what regulatory change will come. The true value of innovation, one panellist commented, is only realised through commercialisation, so there’s an enormous opportunity to work together to make more programmes successful, and in helping them reach market faster.
The Fierce JPM Panel was chaired by Kurt Nielsen, Ph.D., Managing Partner, Expert Insights Consulting, who was joined by panellists: William Humphries, CEO, Alcami; Christian Jones, CCO, Nanoform; Hayley Crowe, EVP & GM of Global Sciences, Ecolab; Dan Smithey, Ph.D., President, CEO & Co-founder, Serán BioScience.
